Kazia Therapeutics
@KaziaTx
Followers
932
Following
148
Statuses
611
@KaziaTx is pleased to share an episode featuring $KZIA CEO and Prof Sudha Rao at @QIMRB_Institute, where they discuss the potential of treating advanced breast cancer with our lead drug candidate #paxalisib.🎧 Listen now: #TNBC #oncology
0
0
0
As seen on @SkyNewsAust, there is an urgent unmet treatment need for advanced breast cancer patients. A new clinical trial by @KaziaTx explores treatment using #paxalisib in combination with immunotherapy. More: $KZIA
0
1
1
@KaziaTx is pleased to announce the launch of a Phase 1b clinical trial, evaluating the safety and efficacy of #paxalisib in combination with #immunotherapy in advanced breast cancer patients. More:
0
0
4
@KaziaTx is pleased to share that a Type C meeting has been granted to the company by the #FDA to discuss potential pathways to the registration of Kazia’s lead asset #paxalisib for #GBM. For more details and an updated Kazia corporate presentation: $KZIA
3
4
12
@KaziaTx congratulates Prof @MattDunn17 on receiving an Australian Society for Medical Research medal. His work around #DIPG treatments provides life-changing benefits for children and their parents who are affected by this deadly childhood #braincancer.
0
0
6
@KaziaTx was pleased to present a poster at the 15th Biennial Ovarian Cancer Research Symposium, highlighting data results from a Phase 1 clinical study of EVT801 in HGS #OvarianCancer. The Phase 1 study met its primary endpoint. More: @RivkinCenter @AACR
0
0
7
A big shout out to all those participating in today’s @RUNDIPG Run 4 Run DIPG event across Australia. Your support to raise much needed funds for research into #DIPG, the deadliest childhood cancer, is hugely appreciated. To donate visit: #R4RD2024
THE COUNTDOWN IS ON! Help us reach our goal of raising $100,000 towards DIPG & DMG awareness and research! 📅Sunday 22nd September 2024 📍Liles Oval, Redhead, NSW 🏃♀️Participate in our Half marathon, 10km or Family 5km! 👉REGISTER NOW:
0
2
10
$KZIA has signed an exclusive worldwide license agreement with @QIMRB_Institute for certain IP rights in relation to the development of drugs within the PI3K inhibitor class in combination with immunotherapy or PARP inhibitors. More here:
1
4
9
September is Childhood Cancer Awareness Month 🎗 We’d like to call out @RUNDIPG in their mission to fight childhood brain #cancer. Join them on Sunday, Sept 22nd, for the #RUN4RUNDIPG event. Learn more: #MovingTowardsACure #childhoodbraincancer #paxalisib
0
0
3
Today is #GlioblastomaAwarenessDay 🧠 Glioblastoma #GBM is an aggressive brain cancer and represents a high unmet treatment need. @KaziaTx is advancing GBM treatment with #paxalisib. Join us to fight against this important cancer disease. More:
0
2
11
🎗️Today is #DIPGAwarenessDay! #DIPG is an aggressive childhood brain cancer and we’d like to acknowledge the work of @MattDun17 and his charity @RunDIPG for their dedication to finding new treatment options. Lend your support #paxalisib #braincancer $KZIA
2
6
19
Watch this interview with Professor Sudha Rao from @QIMRB_Institute, as she shares insights from her team’s research in #epigenetics and the potential role of #paxalisib in treating advanced #BreastCancer $KZIA #breatcancertreatment
1
4
11
May is #BrainTumourAwarenessMonth, when the medical, scientific and patient community come together to raise awareness, support and funding for further research. Learn more here
0
1
5
New corporate update from @KaziaTx is now available, detailing recent advancements and upcoming milestones in our clinical development programs for #paxalisib and EVT-801. More: #oncology #braincancer
1
9
10
Busy few days for @KaziaTx at this year’s @AACR Annual Meeting in California, with two poster presentations on EVT801 and one on #paxalisib as a combination therapy for patients with relapsed/recurrent AT/RT.
2
7
18
Today is #WorldHealthDay and @KaziaTx stands united with the global health community as we continue with our fight to deliver innovative new treatment options to cancer patients worldwide. Discover more on @WHO’s website:
0
3
8
.@KaziaTx licenses #paxalisib to Sovargen for intractable seizures in central nervous system diseases. More here:
4
3
12
.@KaziaTx shares an update on EVT801, our #antiangiogenesis asset. We highlight our ongoing Phase 1 study, where 26 patients have been treated with favorable safety and tolerability to date + next steps in the clinical program. More: #oncology $KZIA
1
6
18